Pbf-999 / 320 mg (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02907294 (ClinicalTrials.gov) | March 2016 | 8/3/2016 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers | Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers | Huntington Disease | Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo | Palobiofarma SL | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Terminated | 18 Years | 45 Years | Both | 8 | Phase 1 | Spain |